Evommune, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Evommune, Inc. (EVMN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Evommune, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.60M, a 725.49% increase year-over-year.
- Evommune, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.45M, a 534.93% increase year-over-year.
- Evommune, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $4.20M, a 749.39% increase year-over-year.
- Evommune, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $561.00K, a 39.90% increase year-over-year.
- Evommune, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $5.86M, a 240.07% increase from fiscal 2024.
- Evommune, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.72M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.60M 10-Q · filed 2026-08-06 | $8.05M 10-Q · filed 2026-08-06 | $12.25M derived: sum of 3 quarters · filed 2026-08-06 | $12.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.45M 10-Q · filed 2026-05-07 | $7.65M derived: sum of 2 quarters · filed 2026-05-07 | $8.21M derived: sum of 3 quarters · filed 2026-05-07 | $8.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.76M derived: sum of 2 quarters · filed 2026-03-05 | $5.31M derived: sum of 3 quarters · filed 2026-08-06 | $5.86M 10-K · filed 2026-03-05 |
| 2025-09-30 | $561.00K 10-Q · filed 2025-12-11 | $1.12M derived: sum of 2 quarters · filed 2026-08-06 | $1.66M 10-Q · filed 2025-12-11 | $2.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $557.00K 10-Q · filed 2026-08-06 | $1.10M 10-Q · filed 2026-08-06 | $1.59M derived: sum of 3 quarters · filed 2026-08-06 | $2.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $544.00K 10-Q · filed 2026-05-07 | $1.04M derived: sum of 2 quarters · filed 2026-05-07 | $1.44M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $494.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $895.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.72M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $401.00K 10-Q · filed 2025-12-11 | $1.23M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |